RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma

PLoS One. 2023 Oct 5;18(10):e0292452. doi: 10.1371/journal.pone.0292452. eCollection 2023.

Abstract

Receptor activity modifying protein 1 (RAMP1) facilitates the localization of the calcitonin-like receptor (CLR) to the plasma membrane, but its role in osteosarcoma (OS) remains unclear. We evaluated the RAMP1 expression and prognostic value across different cancers, studying tumor immune infiltration. The prognostic value was analyzed using the GSE39058 and TARGET datasets. Differential gene expression was evaluated. a protein-protein interaction network was constructed, and gene set enrichment analysis was performed. The function of RAMP1 in the tumor microenvironment was analyzed, and its expression in OS cell lines was validated using quantitative real-time PCR. High RAMP1 expression correlated with poor prognosis relative to low RAMP1 expression (p < 0.05). Low RAMP1 expression correlated with an abundance of CD4+ memory-activated T cells. whereas a high expression level correlated with a high proportion of gamma-delta T cells (γδ T cells). Differentially expressed genes from TARGET was enriched in olfactory transduction pathways (normalized enrichment scores [NES] = 1.6998, p < 0.0001). RAMP1 expression negatively correlated with CD44 expression but positively correlated with TNFSF9 expression. The RAMP1 gene is substantially expressed in OS cells compared to the normal osteoblast cell line hFOB1.19. Thus, RAMP1 may be a prognostic biomarker and potential therapeutic target in OS.

MeSH terms

  • Biomarkers
  • Cell Line
  • Humans
  • Osteosarcoma* / genetics
  • Prognosis
  • Receptor Activity-Modifying Protein 1 / genetics
  • Receptors, Calcitonin* / genetics
  • Receptors, Calcitonin* / metabolism
  • Tumor Microenvironment

Substances

  • Receptor Activity-Modifying Protein 1
  • Receptors, Calcitonin
  • Biomarkers
  • RAMP1 protein, human

Grants and funding

The author(s) received no specific funding for this work.